ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

LGND Ligand Pharmaceuticals Incorporated

85.05
1.09 (1.30%)
May 31 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 122,260
Bid Price 83.05
Ask Price 86.85
News -
Day High 86.82

Low
49.24

52 Week Range

High
94.57

Day Low 84.32
Share Name Share Symbol Market Stock Type
Ligand Pharmaceuticals Incorporated LGND NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
1.09 1.30% 85.05 16:30:00
Open Price Low Price High Price Close Price Previous Close
84.53 84.32 86.82 85.05 83.96
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
3,768 122,260 US$ 85.57 US$ 10,461,313 - 49.24 - 94.57
Last Trade Type Quantity Price Currency
15:20:00 priorref 517 US$ 85.05 USD

Ligand Pharmaceuticals Incorporated Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.51B 17.71M - 131.31M 52.15M 2.95 28.87
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Ligand Pharmaceuticals News

Date Time Source News Article
5/30/202415:03Edgar (US Regulatory)Form 8-K - Current report
5/17/202419:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/17/202418:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/17/202416:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
5/16/202416:39Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
5/15/202418:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/15/202417:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
5/15/202413:45Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]
5/14/202418:42Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
5/09/202415:11Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting..
3/07/202412:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
3/06/202416:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No LGND Message Board. Create One! See More Posts on LGND Message Board See More Message Board Posts

Historical LGND Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week85.6086.8683.08585.30129,798-0.55-0.64%
1 Month73.5388.5272.5783.57156,98611.5215.67%
3 Months73.0688.5267.7276.65168,91311.9916.41%
6 Months58.1294.5757.0075.06153,40626.9346.34%
1 Year69.6094.5749.2470.75126,13415.4522.20%
3 Years117.96169.9849.2493.63144,999-32.91-27.90%
5 Years109.15219.7549.24105.25237,194-24.10-22.08%

Ligand Pharmaceuticals Description

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.